Moderna (NASDAQ:MRNA) Trading Down 3.8% - Time to Sell?

Moderna, Inc. (NASDAQ:MRNA - Get Free Report)'s stock price was down 3.8% on Monday . The company traded as low as $25.62 and last traded at $25.65. Approximately 4,655,272 shares traded hands during mid-day trading, a decline of 45% from the average daily volume of 8,393,897 shares. The stock had previously closed at $26.67.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the stock. Morgan Stanley decreased their price objective on shares of Moderna from $39.00 to $32.00 and set an "equal weight" rating for the company in a report on Wednesday, April 9th. Citigroup began coverage on Moderna in a research report on Thursday, March 13th. They issued a "neutral" rating and a $40.00 target price for the company. Royal Bank Of Canada lowered their price target on Moderna from $32.00 to $28.00 and set a "sector perform" rating on the stock in a research report on Friday, May 2nd. William Blair reissued a "market perform" rating on shares of Moderna in a research note on Monday, June 2nd. Finally, UBS Group cut their price target on shares of Moderna from $78.00 to $70.00 and set a "buy" rating for the company in a report on Friday, May 2nd. Four equities research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, three have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $46.61.

Moderna Stock Down 0.6%

The stock's 50 day moving average price is $26.27 and its two-hundred day moving average price is $32.69. The firm has a market capitalization of $9.82 billion, a price-to-earnings ratio of -2.91 and a beta of 1.86.

Moderna (NASDAQ:MRNA - Get Free Report) last issued its earnings results on Thursday, May 1st. The company reported ($2.52) earnings per share for the quarter, topping the consensus estimate of ($2.92) by $0.40. Moderna had a negative return on equity of 28.69% and a negative net margin of 105.67%. The company had revenue of $108.00 million for the quarter, compared to analyst estimates of $130.35 million. During the same period in the prior year, the firm posted ($3.07) EPS. The business's revenue was down 35.3% compared to the same quarter last year. On average, equities analysts expect that Moderna, Inc. will post -9.61 EPS for the current fiscal year.

Hedge Funds Weigh In On Moderna

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Deutsche Bank AG grew its position in Moderna by 54.7% in the fourth quarter. Deutsche Bank AG now owns 1,894,075 shares of the company's stock worth $78,756,000 after acquiring an additional 669,614 shares in the last quarter. Tang Capital Management LLC acquired a new stake in shares of Moderna in the 4th quarter valued at $12,474,000. Proficio Capital Partners LLC boosted its holdings in Moderna by 4,418.9% in the fourth quarter. Proficio Capital Partners LLC now owns 147,360 shares of the company's stock worth $6,127,000 after purchasing an additional 144,099 shares in the last quarter. South Dakota Investment Council increased its position in Moderna by 4.0% during the fourth quarter. South Dakota Investment Council now owns 299,399 shares of the company's stock worth $12,449,000 after buying an additional 11,500 shares during the last quarter. Finally, BDF Gestion bought a new position in Moderna during the first quarter valued at about $783,000. Institutional investors own 75.33% of the company's stock.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.